|MDACC Study No:||2010-0708 (clinicaltrials.gov NCT No: NCT01363128)|
|Title:||Phase II Study of the Hyper - CVAD Regimen in Combination with Ofatumumab as Frontline Therapy for patients with CD-20 positive Acute Lymphoblastic Leukemia|
|Principal Investigator:||Elias Jabbour|
|Treatment Agent:||Cytarabine; HCVAD; Methotrexate; Ofatumumab|
|Study Description:||The goal of this clinical research study is to learn if ofatumumab combined |
with standard chemotherapy can help to control ALL. The safety of these drug
combinations will also be studied.